UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 132

Sortiert nach

Intravenous N -Acetylcysteine Improves Transplant-Free Survival in Early Stage Non-Acetaminophen Acute Liver Failure

Gastroenterology (New York, N.Y. 1943), 2009-09, Vol.137 (3), p.856-864.e1

2009

Volltextzugriff (PDF)

Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT‐0401 and REVERSE randomised clinical studies

Alimentary pharmacology & therapeutics, 2017-06, Vol.45 (11), p.1390-1402

2017

Volltextzugriff (PDF)

The Natural History of Severe Acute Liver Injury

The American journal of gastroenterology, 2017-09, Vol.112 (9), p.1389-1396

2017

Volltextzugriff (PDF)

Fluid retention in cirrhosis: pathophysiology and management

QJM, 2008-02, Vol.101 (2), p.71-85

2008

Volltextzugriff (PDF)

Wilson disease—A practical approach to diagnosis, treatment and follow-up

Digestive and liver disease, 2007-07, Vol.39 (7), p.601-609

2007

Volltextzugriff (PDF)

Efficacy and safety of ledipasvir/sofosbuvir, with or without ribavirin, for treatment of hepatitis C virus-mono and HCV/HIV co-infected patients who have failed prior treatment with non-NS5A, SOF-based therapies

Journal of hepatology, 2017, Vol.66 (1), p.S307-S307

2017

Volltextzugriff (PDF)

2016 LONG-TERM OUTCOMES FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEG-INTRON/RIBAVIRIN (P/R) IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1 (CHC-G1)

Journal of hepatology, 2010, Vol.52, p.S470-S471

2010

Volltextzugriff (PDF)

O61 EFFICACY AND SAFETY OF MK-5172 AND MK-8742 ± RIBAVIRIN IN HEPATITIS C GENOTYPE 1 INFECTED PATIENTS WITH CIRRHOSIS OR PREVIOUS NULL-RESPONSE: THE C-WORTHY STUDY

Journal of hepatology, 2014-04, Vol.60 (1), p.S25-S26

2014

Volltextzugriff (PDF)

O56 SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN FOR 8 WEEKS COMPARED TO SOFOSBUVIR/LEDIPASVIR FOR 12 WEEKS IN TREATMENT-NAÏVE NON-CIRRHOTIC GENOTYPE-1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-3 STUDY

Journal of hepatology, 2014-04, Vol.60 (1), p.S23-S24

2014

Volltextzugriff (PDF)

64 GS-5885 + GS-9451 + PEGINTERFERON AND RIBAVIRIN (PR) FOR SIX OR TWELVE WEEKS ACHIEVES HIGH SVR12 RATES IN TREATMENT-NAÏVE GENOTYPE 1 IL28B CC PATIENTS

Journal of hepatology, 2013-04, Vol.58, p.S29-S29

2013

Volltextzugriff (PDF)

109 LONG TERM EFFICACY AND SURVIVAL IN PATIENTS TREATED WITH THE GUT-SELECTIVE ANTIBIOTIC RIFAXIMIN (550 MG BID) FOR THE MAINTENANCE OF REMISSION FROM OVERT HEPATIC ENCEPHALOPATHY

Journal of hepatology, 2011-03, Vol.54, p.S49-S49

2011

Volltextzugriff (PDF)

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

The New England journal of medicine, 2011-03, Vol.364 (13), p.1195-1206

2011

Volltextzugriff (PDF)

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

The New England journal of medicine, 2011-03, Vol.364 (13), p.1207-1217

2011

Volltextzugriff (PDF)

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

The New England journal of medicine, 2011-09, Vol.365 (11), p.1014-1024

2011

Volltextzugriff (PDF)

466 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 WHEN TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (PR)

Journal of hepatology, 2011-03, Vol.54, p.S190-S190

2011

Volltextzugriff (PDF)

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

The New England journal of medicine, 2009-08, Vol.361 (6), p.580-593

2009

Volltextzugriff (PDF)

Brief report : No evidence for parvovirus B19 or hepatitis E virus as a cause of acute liver failure

Digestive diseases and sciences, 2006-10, Vol.51 (10), p.1712-1715

2006

Volltextzugriff (PDF)

Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: Relationship of serum creatinine to hemodynamics

Journal of hepatology, 2011-08, Vol.55 (2), p.315-321

2011

Volltextzugriff (PDF)

Intensive care of patients with acute liver failure: Recommendations of the U.S. Acute Liver Failure Study Group

Critical care medicine, 2007-11, Vol.35 (11), p.2498-2508

2007

Volltextzugriff (PDF)

Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1

Liver transplantation, 2011-11, Vol.17 (11), p.1328-1332

2011

Volltextzugriff (PDF)

304 METABOLIC SYNDROME (MS) IS A NEGATIVE PREDICTOR OF TREATMENT OUTCOME IN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS FROM THE IDEAL STUDY

Journal of hepatology, 2010, Vol.52, p.S127-S128

2010

Volltextzugriff (PDF)

778 PHASE IIB STUDY OF BALAPIRAVIR (RG1626; NUCLEOSIDE ANALOGUE INHIBITOR OF HCV POLYMERASE) PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOR CHC GENOTYPE 1: FINAL RESULTS

Journal of hepatology, 2010, Vol.52, p.S302-S303

2010

Volltextzugriff (PDF)

830 VIROLOGIC RESPONSES TO PEGINTERFERON ALFA-2A/RIBAVIRIN IN TREATMENT-NAIVE LATINO VS NON-LATINO CAUCASIANS INFECTED WITH HCV GENOTYPE 1: THE LATINO STUDY

Journal of hepatology, 2008, Vol.48, p.S311-S311

2008

Volltextzugriff (PDF)

Sudden infant death syndrome: The colon connection

Medical hypotheses, 2006, Vol.66 (2), p.375-379

2006

Volltextzugriff (PDF)

1 – 25 von 132

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(122)
Mit Volltextzugriff
(112)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(78)
Life Sciences & Biomedicine
(77)
Humans
(69)
Female
(47)
Male
(46)
Adult
(41)
Middle Aged
(41)
Biological And Medical Sciences
(37)
Gastroenterology & Hepatology
(34)
Medical Sciences
(33)
Aged
(21)
Liver Transplantation
(19)
Gastroenterology And Hepatology
(17)
Drug Therapy, Combination
(14)
Antiviral Agents - Adverse Effects
(12)
Chironomidae
(12)
Hepatitis
(12)
Hepatitis C, Chronic - Drug Therapy
(11)
Adolescent
(10)
Animals
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Intravenous N -Acetylcysteine Improves Transplant-Free Survival in Early Stage Non-Acetaminophen Acute Liver Failure

Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT‐0401 and REVERSE randomised clinical studies

The Natural History of Severe Acute Liver Injury

Fluid retention in cirrhosis: pathophysiology and management

Wilson disease—A practical approach to diagnosis, treatment and follow-up

Efficacy and safety of ledipasvir/sofosbuvir, with or without ribavirin, for treatment of hepatitis C virus-mono and HCV/HIV co-infected patients who have failed prior treatment with non-NS5A, SOF-based therapies

2016 LONG-TERM OUTCOMES FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEG-INTRON/RIBAVIRIN (P/R) IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1 (CHC-G1)

O61 EFFICACY AND SAFETY OF MK-5172 AND MK-8742 ± RIBAVIRIN IN HEPATITIS C GENOTYPE 1 INFECTED PATIENTS WITH CIRRHOSIS OR PREVIOUS NULL-RESPONSE: THE C-WORTHY STUDY

O56 SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN FOR 8 WEEKS COMPARED TO SOFOSBUVIR/LEDIPASVIR FOR 12 WEEKS IN TREATMENT-NAÏVE NON-CIRRHOTIC GENOTYPE-1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-3 STUDY

64 GS-5885 + GS-9451 + PEGINTERFERON AND RIBAVIRIN (PR) FOR SIX OR TWELVE WEEKS ACHIEVES HIGH SVR12 RATES IN TREATMENT-NAÏVE GENOTYPE 1 IL28B CC PATIENTS

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

109 LONG TERM EFFICACY AND SURVIVAL IN PATIENTS TREATED WITH THE GUT-SELECTIVE ANTIBIOTIC RIFAXIMIN (550 MG BID) FOR THE MAINTENANCE OF REMISSION FROM OVERT HEPATIC ENCEPHALOPATHY

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

466 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 WHEN TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (PR)

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

Brief report : No evidence for parvovirus B19 or hepatitis E virus as a cause of acute liver failure

Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: Relationship of serum creatinine to hemodynamics

Intensive care of patients with acute liver failure: Recommendations of the U.S. Acute Liver Failure Study Group

Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1

304 METABOLIC SYNDROME (MS) IS A NEGATIVE PREDICTOR OF TREATMENT OUTCOME IN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS FROM THE IDEAL STUDY

778 PHASE IIB STUDY OF BALAPIRAVIR (RG1626; NUCLEOSIDE ANALOGUE INHIBITOR OF HCV POLYMERASE) PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOR CHC GENOTYPE 1: FINAL RESULTS

830 VIROLOGIC RESPONSES TO PEGINTERFERON ALFA-2A/RIBAVIRIN IN TREATMENT-NAIVE LATINO VS NON-LATINO CAUCASIANS INFECTED WITH HCV GENOTYPE 1: THE LATINO STUDY

Sudden infant death syndrome: The colon connection

Suchergebnisse filtern